PMID- 20607649
OWN - NLM
STAT- MEDLINE
DCOM- 20110425
LR  - 20121115
IS  - 1439-0221 (Electronic)
IS  - 0032-0943 (Linking)
VI  - 77
IP  - 1
DP  - 2011 Jan
TI  - MAPKs are not involved in triptolide-induced cell growth inhibition and apoptosis 
      in prostate cancer cell lines with different p53 status.
PG  - 27-31
LID - 10.1055/s-0030-1250076 [doi]
AB  - Triptolide showed excellent antitumor activity against several solid tumors. 
      However, its mechanism has not been fully understood. To further elucidate it, 
      the effects of mitogen activated protein kinases (MAPKs) on the activity of 
      triptolide towards prostate cancer cell lines were investigated in the present 
      study using both LNCaP (p53 positive and androgen-dependent) and PC-3 (p53 
      deficient and androgen-independent) cells. Our results showed that triptolide 
      exerted potent growth inhibitory and apoptotic effects on both cell lines, and 
      the effects were independent of the expression of p53. Although upregulation of 
      ERK and JNK phosphorylation was observed after the triptolide treatment, the 
      results with inhibitors showed that these MAPKs were not involved in the 
      mechanism of triptolide activity in human prostate cancer cell lines with 
      different p53 status.
CI  - (c) Georg Thieme Verlag KG Stuttgart . New York.
FAU - Li, Wei
AU  - Li W
AD  - Laboratory of Pharmaceutical Resource Discovery, Dalian Institute of Chemical 
      Physics, Chinese Academy of Sciences, Dalian, China.
FAU - Liu, Yong
AU  - Liu Y
FAU - Li, Xue-Xia
AU  - Li XX
FAU - Yu, Yang
AU  - Yu Y
FAU - Wu, Jing-Jing
AU  - Wu JJ
FAU - Wang, Qing
AU  - Wang Q
FAU - Huo, Hong
AU  - Huo H
FAU - Wang, Li-Ming
AU  - Wang LM
FAU - Yang, Ling
AU  - Yang L
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20100706
PL  - Germany
TA  - Planta Med
JT  - Planta medica
JID - 0066751
RN  - 0 (Antineoplastic Agents, Alkylating)
RN  - 0 (Cytostatic Agents)
RN  - 0 (Diterpenes)
RN  - 0 (Epoxy Compounds)
RN  - 0 (Phenanthrenes)
RN  - 0 (Protein Kinase Inhibitors)
RN  - 0 (Tumor Suppressor Protein p53)
RN  - 19ALD1S53J (triptolide)
RN  - EC 2.7.11.24 (Mitogen-Activated Protein Kinases)
SB  - IM
MH  - Antineoplastic Agents, Alkylating/*pharmacology/therapeutic use
MH  - Apoptosis/*drug effects
MH  - Cell Line, Tumor
MH  - Cytostatic Agents/*pharmacology/therapeutic use
MH  - Diterpenes/*pharmacology/therapeutic use
MH  - Epoxy Compounds/pharmacology/therapeutic use
MH  - Humans
MH  - MAP Kinase Signaling System
MH  - Male
MH  - Mitogen-Activated Protein Kinases/antagonists & inhibitors/*physiology
MH  - Phenanthrenes/*pharmacology/therapeutic use
MH  - Prostatic Neoplasms/*drug therapy/enzymology/pathology
MH  - Protein Kinase Inhibitors/pharmacology
MH  - Tumor Suppressor Protein p53/*metabolism
EDAT- 2010/07/08 06:00
MHDA- 2011/04/26 06:00
CRDT- 2010/07/08 06:00
PHST- 2010/07/08 06:00 [entrez]
PHST- 2010/07/08 06:00 [pubmed]
PHST- 2011/04/26 06:00 [medline]
AID - 10.1055/s-0030-1250076 [doi]
PST - ppublish
SO  - Planta Med. 2011 Jan;77(1):27-31. doi: 10.1055/s-0030-1250076. Epub 2010 Jul 6.